leisure time -WSS

leisure time

author：explore 2025-09-28 23:31:21 - browse：291

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： STAT Readout Newsletter: Today's biggest biotech updates

focus

WSS

Hospital price transparency does save money, advocate argues

Medicare Advantage coverage denials need scrutiny, senators say

Ascension's ugly legal battle over care for poor patients in Texas

Studies point to risks of excluding people with obesity from drug trials

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Fauci's latest grilling in Congress: 9 hours, behind closed doors

hotspot

leisure time

Wikipedia

How one medical school became remarkably diverse

FDA struggles to regulate food additives, sometimes for decades

Trump demands the U.S. pay no more for drugs than other countries … again

Pharmacists can make shortage drugs, but at what cost?

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

How to save PrEP access — and even expand it

Profiling embryos to choose those with higher IQs is almost a reality

Guidelines to prevent youth baseball injuries need more muscle

Pharmacists can make shortage drugs, but at what cost?

Wikipedia

The EU Joint Clinical Assessment needs to live up to its promise

Boston Scientific acquires urology company Axonics for $3.7 billion

The EU Joint Clinical Assessment needs to live up to its promise

Study suggests new cause of Down syndrome: cells linked to aging

Solve the antibiotic resistance crisis with preventive drugs

The EU Joint Clinical Assessment needs to live up to its promise

focus

focus

entertainment

focus